Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha) (IL3RA), NKp46 (natural cytotoxicity triggering receptor 1) (NCR1) and CD16 (Fc gamma receptor IIIa) (FCGR3A) · developed by Sanofi
Bexatamig is a tri-specific natural killer cell engager that binds CD123 on tumor cells and simultaneously binds the activating NK cell receptors NKp46 and CD16. This brings CD123-expressing cells and NK cells together, stimulating NK cells to lyse CD123-expressing tumor cells. It is being studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
Acute Myeloid Leukemia
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →